The April 2026 DOJ order, following President Trump’s December 2025 executive directive, immediately moved FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III under the Controlled Substances Act, effective April 28. This partial action via administrative order bypassed prior stalled rulemaking and reflects administration priorities on research access while preserving controls on non-medical use. An expedited DEA hearing, set to begin June 29 and conclude by July 15, 2026, will now evaluate broader rescheduling of all marijuana to Schedule III through formal rulemaking. Trader consensus on timelines for full rescheduling hinges on the hearing’s outcome, potential Federal Register publication shortly afterward, and any resulting litigation or procedural delays, against the backdrop of longstanding HHS recommendations and state medical programs.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano$764,577 Wol.
June 30
2%
December 31
27%
$764,577 Wol.
June 30
2%
December 31
27%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Rynek otwarty: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...The April 2026 DOJ order, following President Trump’s December 2025 executive directive, immediately moved FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III under the Controlled Substances Act, effective April 28. This partial action via administrative order bypassed prior stalled rulemaking and reflects administration priorities on research access while preserving controls on non-medical use. An expedited DEA hearing, set to begin June 29 and conclude by July 15, 2026, will now evaluate broader rescheduling of all marijuana to Schedule III through formal rulemaking. Trader consensus on timelines for full rescheduling hinges on the hearing’s outcome, potential Federal Register publication shortly afterward, and any resulting litigation or procedural delays, against the backdrop of longstanding HHS recommendations and state medical programs.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania